A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Nonalcoholic Steatohepatitis (NASH)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2017
At a glance
- Drugs GS 9674 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 13 Jul 2017 Planned number of patients changed from 125 to 140.
- 11 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 23 May 2017 This trial has been completed in Austria as per European Clinical Trials Database record.